



## **AcelRx to Announce Fourth Quarter 2019 Results on Monday, March 16th, 2020**

March 11, 2020

REDWOOD CITY, Calif., March 11, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and annual financial results before market open on Monday, March 16, 2020. AcelRx management will host a live webcast and conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on March 16, 2020 to discuss the financial results and provide an update on the company's business.

The webcast is accessible by visiting the Investors page of the company's website at [www.acelrx.com](http://www.acelrx.com) and clicking on the webcast link on the Investors home page. The webcast will be accompanied by a slide presentation. A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at [www.acelrx.com](http://www.acelrx.com).

Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4204 for international callers.

### **About AcelRx Pharmaceuticals, Inc.**

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA<sup>®</sup> (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso<sup>®</sup> (sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is an investigational drug and not approved in the U.S. For additional information about AcelRx, please visit [www.acelrx.com](http://www.acelrx.com).



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/acelrx-to-announce-fourth-quarter-2019-results-on-monday-march-16th-2020-301021961.html>

SOURCE AcelRx Pharmaceuticals, Inc.

Media, Theresa Dolge, Evoke, 215-928-2748, [theresa.dolge@evokegroup.com](mailto:theresa.dolge@evokegroup.com); Media, Lindsay Barnes, Evoke, 215-928-2194, [lindsay.barnes@evokegroup.com](mailto:lindsay.barnes@evokegroup.com); Investor Contact, Raffi Asadorian, CFO, AcelRx, [investors@acelrx.com](mailto:investors@acelrx.com); Investor Contact, Brian Korb, Solebury Trout, 646-378-2923, [investors@acelrx.com](mailto:investors@acelrx.com)